Dynavax's Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations

Hong Kong-listed Clover Biopharmaceuticals Ltd announced data from a global Phase 2/3 trial evaluating its COVID-19 vaccine candidate, SCB-2019, in adolescents (aged 12 to 17 years).
Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax Technologies Corporation's DVAX CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
The study met the primary endpoint and demonstrated that SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents compared to young adults (aged 18 to 25). In this population, SCB-2019 (CpG 1018/Alum) was highly protective against COVID-19.
Related: Dynavax's Adjuvant-Based Bivalent COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action.
Clover plans to submit the data and seek licensure in adolescents from global regulatory authorities, in addition to its ongoing submissions to the regulatory authorities in China, Europe, and the World Health Organization (WHO) for use in adults and the elderly, to broaden the potential use of SCB-2019 (CpG 1018/Alum) across age groups and as a universal COVID-19 booster vaccine.
The Phase 2/3 trial enrolled 1,278 participants.
Price Action: DVAX shares are up 1.89% at $11.83 on the last check Thursday.